Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in Vivo

Journal of Korean Medical Science

Volumn 26, Issue 10, 2011, Pages 1270-1276

  Oh, So Mi ^a   Oh, Keunhee ^a   Lee, Dong Sup ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

CpG ODN; Melanoma; SLC; Tumor immunotherapy

Indexed keywords

CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; GLYCOPROTEIN P 15095; OLIGODEOXYRIBONUCLEOTIDE; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANIMAL; ARTICLE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; DENDRITIC CELL; DRUG EFFECT; EXPERIMENTAL MELANOMA; IMMUNOLOGY; IMMUNOTHERAPY; INTRALESIONAL DRUG ADMINISTRATION; METABOLISM; MOUSE; NEUTROPHIL CHEMOTAXIS; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD11C; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL21; CHEMOTAXIS, LEUKOCYTE; DENDRITIC CELLS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES;

EID: 84863040959     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2011.26.10.1270     Document Type: Article

References (30)

1. Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol 2006; 90: 243-95.
2. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311: 17-58.
3. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4:540-50.
4. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004; 22: 891-928.
5. Randall TD, Carragher DM, Rangel-Moreno J. Development of secondary lymphoid organs. Annu Rev Immunol 2008; 26: 627-50.
6. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999; 189: 447-50.
7. Chan VW, Kothakota S, Rohan MC, Panganiban-Lustan L, Gardner JP, Wachowicz MS, Winter JA, Williams LT. Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells. Blood 1999; 93:3610-6.
8. Yoshida R, Nagira M, Kitaura M, Imagawa N, Imai T, Yoshie O. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. J Biol Chem 1998; 273: 7118-22.
9. Jenh CH, Cox MA, Kaminski H, Zhang M, Byrnes H, Fine J, Lundell D, Chou CC, Narula SK, Zavodny PJ. Cutting edge: species specificity of the CC chemokine 6Ckine signaling through the CXC chemokine receptor CXCR3: human 6Ckine is not a ligand for the human or mouse CXCR3 receptors. J Immunol 1999; 162: 3765-9.
10. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984; 72: 955-62.
11. Kleeberg UR, Engel E, Israels P, Bröcker EB, Tilgen W, Kennes C, Gérard B, Lejeune F, Glabbeke MV, Lentz MA. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumor load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 1995; 5: 195-200.
12. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
13. Jones TR, Obaldia N 3rd, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 1999; 17: 3065-71.
14. Vabulas RM, Pircher H, Lipford GB, Häcker H, Wagner H. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol 2000; 164: 2372-8.
15. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998; 161: 3042-9.
16. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control 2002; 9: 16-21.
17. Lo JC, Chin RK, Lee Y, Kang HS, Wang Y, Weinstock JV, Banks T, Ware CF, Franzoso G, Fu YX. Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. J Clin Invest 2003; 112: 1495-505.
18. Krautwald S, Ziegler E, Förster R, Ohl L, Amann K, Kunzendorf U. Ectopic expression of CCL19 impairs alloimmune response in mice. Immunology 2004; 112: 301-9.
19. Yang SH, Oh TK, Kim ST. Increased anti-tumor effect by a combination of HSV thymidine kinase suicide gene therapy and interferon-gamma/ GM-CSF cytokine gene therapy in CT26 tumor model. J Korean Med Sci 2005; 20: 932-7.
20. Park JN, Suh C, Yang J, Park JS, Park KU, Min YJ, Kim HJ, Kim YH, Kim SH. Active immunization using dendritic cells mixed with tumor cells inhibits the growth of lymphomas. J Korean Med Sci 2003; 18: 372-80.
21. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004; 10: 187-92.
22. Dubinett SM, Lee JM, Sharma S, Mulé JJ. Chemokines: can effector cells be redirected to the site of the tumor? Cancer J 2010; 16: 325-35.
23. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 2007; 109: 2392-404.
24. Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D. CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol 2005; 174: 5856-63.
25. Shurin GV, Ferris RL, Tourkova IL, Perez L, Lokshin A, Balkir L, Collins B, Chatta GS, Shurin MR. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol 2005; 174: 5490-8.
26. Thanarajasingam U, Sanz L, Diaz R, Qiao J, Sanchez-Perez L, Kottke T, Thompson J, Chester J, Vile RG. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res 2007; 67: 300-8.
27. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, Lebecque S, Fridman WH, Cadranel J. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410-7.
28. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. Induction of lymphoid like stroma and immune escape by tumors that express the chemokine CCL21. Science 2010; 328: 749-52.
29. Hisada M, Yoshimoto T, Kamiya S, Magami Y, Miyaji H, Yoneto T, Tamada K, Aoki T, Koyanagi Y, Mizuguchi J. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Ther 2004; 11: 280-8.
30. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004; 5: 141-9.